{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:34:53Z","timestamp":1760060093190,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Farmac\u00e9utica S.A. (Spain)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: The advent of tyrosine kinase inhibitors (TKIs) revolutionized the management of chronic myeloid leukemia (CML), achieving survival rates near those of the general population. Despite this success, prolonged therapy presents challenges, including physical, emotional, and financial burdens. Treatment-free remission (TFR), defined as sustained deep molecular response (DMR) after discontinuing TKIs, has emerged as a viable clinical goal. This study evaluates real-world data from the Canary Islands Registry of CML (RCLMC) to explore outcomes, predictors, and the feasibility of TFR. Methods: This retrospective observational study included 393 patients diagnosed with CML-CP between 2007 and 2023. Molecular response was monitored according to international guidelines. Survival probabilities were estimated using the Kaplan\u2013Meier method. Logistic regression analysis was performed to identify predictors of molecular relapses after TKI discontinuation. Results: Of the 383 patients who received TKI treatment, 58.3% achieved molecular response grade 2 (MR2) (BCR-ABL1 \u2264 1%), 95.05% achieved MR2, and 50.5% reached MR4 within the first year. Of the 107 patients attempting TFR, 73.2% maintained remission at 36 months. Relapses occurred in 24 patients, all regaining molecular response upon reintroduction of TKIs. No cases of disease progression were observed. Conclusions: Our findings support the feasibility and safety of TFR in a real-world clinical setting for well-selected patients, with outcomes consistent with international studies. The study underscores the importance of molecular monitoring and patient-specific strategies to optimize outcomes.<\/jats:p>","DOI":"10.3390\/hematolrep17040039","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:30:06Z","timestamp":1754321406000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TKI Use and Treatment-Free Remission in Chronic Myeloid Leukemia: Evidence from a Regional Cohort Study in the Canary Islands"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-8003","authenticated-orcid":false,"given":"Santiago","family":"S\u00e1nchez-Sosa","sequence":"first","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negrin (HUGCDN), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Specific Didactics, Faculty of Education, Universidad de Las Palmas de Gran Canaria (ULPGC), 35004 Las Palmas de Gran Canaria, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Canarias (IISC), 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-2290","authenticated-orcid":false,"given":"Ruth","family":"Stuckey","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negrin (HUGCDN), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Canarias (IISC), 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Segura D\u00edaz","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negrin (HUGCDN), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Canarias (IISC), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Medical and Surgical Sciences, Faculty of Health Sciences, Universidad de Las Palmas de Gran Canaria (ULPGC), 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 David","family":"Gonz\u00e1lez San Miguel","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Insular de Gran Canaria Materno Infantil (CHUIMI), 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylenia","family":"Morales Ruiz","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Insular de Gran Canaria Materno Infantil (CHUIMI), 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil Lakhawani","family":"Lakhawani","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Canarias (CHUC), 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda Raya","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Canarias (CHUC), 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Moreno Vega","sequence":"additional","affiliation":[{"name":"Hospital Jos\u00e9 Molina Orosa (HJMO), 35500 Arrecife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Tapia Torres","sequence":"additional","affiliation":[{"name":"Hospital General de La Palma (HGP), 38713 Bre\u00f1a Alta, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"L\u00f3pez-Coronado","sequence":"additional","affiliation":[{"name":"Hospital General de Fuerteventura (HGF), 35600 Puerto del Rosario, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda de las Nieves Saez","family":"Perdomo","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negrin (HUGCDN), 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria de Canarias (IISC), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Complejo Hospitalario Universitario de Canarias (CHUC), 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Stoica","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria de Canarias (IISC), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Complejo Hospitalario Universitario de Canarias (CHUC), 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bilbao Sieyro","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negrin (HUGCDN), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Specific Didactics, Faculty of Education, Universidad de Las Palmas de Gran Canaria (ULPGC), 35004 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Morphology, Faculty of Health Sciences, Universidad de Las Palmas de Gran Canaria (ULPGC), 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez Casares","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negrin (HUGCDN), 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Specific Didactics, Faculty of Education, Universidad de Las Palmas de Gran Canaria (ULPGC), 35004 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Medical and Surgical Sciences, Faculty of Health Sciences, Universidad de Las Palmas de Gran Canaria (ULPGC), 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Abruzzese, E., Bocchia, M., Trawinska, M.M., Raspadori, D., Bondanini, F., Sicuranza, A., Pacelli, P., Re, F., Cavalleri, A., and Farina, M. (2023). Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: Comparison of RT-qPCR, d-PCR and CD26+ stem cell measurements in chronic myeloid leukemia (CML) patients in deep molecular response (DMR). Cancers, 15.","DOI":"10.3390\/cancers15164112"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.5306\/wjco.v11.i12.996","article-title":"Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia","volume":"11","author":"Stuckey","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia from pathophysiology to treatment-free remission: A narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J. Blood Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE","volume":"202","author":"Shah","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11899-023-00688-6","article-title":"The bone marrow immune microenvironment in CML: Treatment responses, treatment-free remission, and therapeutic vulnerabilities","volume":"18","author":"Patterson","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11912-022-01228-w","article-title":"Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: A review of the biological factors associated with treatment-free remission","volume":"24","author":"Stuckey","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41375-022-01607-z","article-title":"Standardization of molecular monitoring of CML: Results and recommendations from the European treatment and outcome study","volume":"36","author":"White","year":"2022","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00277-022-04955-z","article-title":"Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: Data from the French observatory","volume":"101","author":"Saugues","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.19269","article-title":"How to improve treatment-free remission eligibility in chronic myeloid leukaemia?","volume":"204","author":"Costa","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_11","first-page":"1752","article-title":"Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial","volume":"37","author":"Boquimpani","year":"2023","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mu, H., Zhu, X., Jia, H., Zhou, L., and Liu, H. (2021). Combination therapies in chronic myeloid leukemia for potential treatment-free remission: Focus on leukemia stem cells and immune modulation. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.643382"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_14","first-page":"506","article-title":"Treatment-free remission in patients with chronic myeloid leukemia","volume":"107","author":"Cayuela","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","first-page":"654","article-title":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: Results from the EURO-SKI Trial","volume":"36","author":"Efficace","year":"2021","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Iurlo, A., Cattaneo, D., Consonni, D., Castagnetti, F., Miggiano, M.C., Binotto, G., Bonifacio, M., Rege-Cambrin, G., Tiribelli, M., and Lunghi, F. (2023). Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1154377"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Karg, E., Baldow, C., Zerjatke, T., Clark, R.E., Roeder, I., Fassoni, A.C., and Glauche, I. (2022). Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1028871"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbou","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","article-title":"Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: Managing intolerance and resistance","volume":"38","author":"Claudiani","year":"2024","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17474086.2020.1717944","article-title":"What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?","volume":"13","author":"Harrington","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1002\/cam4.6296","article-title":"Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/4\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:22:55Z","timestamp":1760034175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/4\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["hematolrep17040039"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17040039","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}